Page last updated: 2024-10-25

denbufylline and Lupus Erythematosus, Systemic

denbufylline has been researched along with Lupus Erythematosus, Systemic in 1 studies

denbufylline: structure given in first source

Lupus Erythematosus, Systemic: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

Research Excerpts

ExcerptRelevanceReference
"Systemic lupus erythematosus is a polymorphic and multigenic inflammatory autoimmune disease."1.38Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor. ( Bourguignon, JJ; Gazi, L; Keravis, T; Lugnier, C; Monneaux, F; Muller, S; Yougbaré, I, 2012)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Keravis, T1
Monneaux, F1
Yougbaré, I1
Gazi, L1
Bourguignon, JJ1
Muller, S1
Lugnier, C1

Other Studies

1 other study available for denbufylline and Lupus Erythematosus, Systemic

ArticleYear
Disease progression in MRL/lpr lupus-prone mice is reduced by NCS 613, a specific cyclic nucleotide phosphodiesterase type 4 (PDE4) inhibitor.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adenine; Animals; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Disease Progression; Fem

2012